Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
November 21, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 12, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update
November 07, 2024 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701) - First data expected to be presented in Q1 2025Presented New CRB-913...
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
November 04, 2024 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight loss in DIO miceSemaglutide treatment...
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
October 29, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
October 16, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio,...
Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit
September 26, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the Company will participate in BMO Capital...
Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference
September 05, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
August 20, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of...
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 06, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancerCRB-701 Phase 1 dose...